Search

everythinglearnresearchcommunity

for

Search:↓

TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.

IL-17 and certain immune cells are linked to more severe alopecia areata.

Blocking interferon-gamma might help treat various autoimmune diseases.

The combination therapy of PEG-IFN α-2a and Ribavirin can cause widespread hair loss and skin reactions.

TNFα, IFNγ, and Substance P significantly affect prolactin levels in human skin, suggesting new treatments for skin and hair conditions.

Plasmacytoid dendritic cells, which overproduce IFN-α, may play a crucial role in starting alopecia areata, an autoimmune disease causing hair loss.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.

Hair follicles are normally protected from the immune system, but when this protection fails, it can cause hair loss in alopecia areata.

New treatments for Alopecia Areata show promise but need to be more effective and affordable.

Animal models have helped understand hair loss from alopecia areata and find new treatments.

Lichen Planopilaris and Frontal Fibrosing Alopecia may help us understand hair follicle stem cell disorders and suggest new treatments.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.

Keratin 17 is linked to various diseases, including cancer and skin conditions, and may be a target for diagnosis and treatment.

The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.

New methods to improve the healing abilities of mesenchymal stem cells for disease treatment are promising but need more research.

Alopecia areata shows a unique type 1 interferon signature, suggesting potential treatment by targeting this pathway.

CGRP may help protect hair follicles from immune system attacks, potentially slowing hair loss.

A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.

Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.

Alopecia areata severity and treatment response are linked to specific cytokine levels.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Trichloroethylene causes skin inflammation in mice by increasing certain immune proteins.

Frontal fibrosing alopecia is linked to increased immune system activity and reduced stem cells, suggesting early treatment targeting this pathway might prevent hair follicle damage.

Skin problems like itching, dry skin, and hair loss are more common in hepatitis C patients after interferon treatment, but lichen planus is not linked to the infection.

Alopecia Areata might be linked to Crohn's disease.

JAK inhibitors helped treat hair loss in two people with Down syndrome.

Type I interferons play a key role in the development of various skin diseases.

APS-1 in Italy shows diverse AIRE mutations and various autoimmune issues.